Harvard Bioscience Files 8-K Report
Ticker: HBIO · Form: 8-K · Filed: Dec 5, 2025 · CIK: 1123494
| Field | Detail |
|---|---|
| Company | Harvard Bioscience Inc (HBIO) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
Related Tickers: HBIO
TL;DR
HBIO filed an 8-K on 12/5/25 for 'Other Events' - need more info.
AI Summary
On December 5, 2025, Harvard Bioscience, Inc. filed an 8-K report. The filing indicates "Other Events" as the item information, with no specific details provided in the excerpt regarding the nature of these events, any associated financial figures, or other involved parties.
Why It Matters
This filing signals a material event has occurred for Harvard Bioscience, Inc., requiring public disclosure. Investors should monitor for further details to understand the event's implications.
Risk Assessment
Risk Level: low — The filing is a standard disclosure form without immediate negative or positive financial implications detailed in the provided text.
Key Players & Entities
- Harvard Bioscience, Inc. (company) — Registrant
- December 5, 2025 (date) — Date of earliest event reported
FAQ
What specific event is Harvard Bioscience, Inc. reporting under 'Other Events'?
The provided excerpt does not specify the nature of the 'Other Events' being reported by Harvard Bioscience, Inc.
When was this 8-K report filed?
The 8-K report was filed on December 5, 2025.
What is the principal executive office address for Harvard Bioscience, Inc.?
The principal executive office is located at 84 October Hill Road, Holliston, MA 01746.
What is Harvard Bioscience, Inc.'s telephone number?
The registrant's telephone number is (508) 893-8999.
What is the SIC code for Harvard Bioscience, Inc.?
The Standard Industrial Classification code for Harvard Bioscience, Inc. is 3826, which corresponds to Laboratory Analytical Instruments.
Filing Stats: 406 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2025-12-05 16:30:30
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value HBIO The NASDAQ Capital Mar
Filing Documents
- f8k_120525.htm (8-K) — 19KB
- logo.jpg (GRAPHIC) — 7KB
- 0001171843-25-007776.txt ( ) — 196KB
- hbio-20251205.xsd (EX-101.SCH) — 3KB
- hbio-20251205_lab.xml (EX-101.LAB) — 33KB
- hbio-20251205_pre.xml (EX-101.PRE) — 22KB
- f8k_120525_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events The Company is engaged in ongoing discussions relating to its existing credit agreement, dated December 22, 2020, as amended, with Citizens Bank, N.A., Wells Fargo Bank, N.A., and First-Citizens Bank & Trust Company (the "Credit Agreement"), and remains on track to complete the refinancing or repayment of the Credit Agreement during the fourth quarter of 2025. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARVARD BIOSCIENCE, INC. Date: December 5, 2025 By: /s/ Mark Frost Mark Frost Interim Chief Financial Officer